{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:26:04Z","timestamp":1777929964157,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Die Analyse der Ergebnisse der kooperativen Therapiestudien BFM 78 und 83 zur Behandlung der akuten myeloischen Leuk\u00e4mie im Kindesaiter ergab folgende Risikofaktoren: Todesf\u00e4lle vor Therapiebeginn und Fr\u00fchtodesf\u00e4lle traten signifikant h\u00e4ufiger bei Patienten mit akuter Monoblasten\/Monozytenleuk\u00e4mie und mit hohen initialen Leukozytenzahlen \u00fcber 100000\/\u03bcl auf als in den \u00fcbrigen Gruppen. Die Remissionsrate lag bei Kindern mit initialen Leukozytenzahlen \u00fcber 100000\/\u03bcl deutlich niedriger (56%) als bei Kindern mit Leukozytenzahlen unter 100000\/\u03bcl (86%). In Remission gelangte Kinder der Therapiestudie BFM 78 mit initialen Leukozytenzahlen \u00fcber 100 000\/\u03bcl haben eine signifikant geringere Wahrscheinlichkeit eines rezidivfreien Intervalls von 6 Jahren (pCCR = 28 %; SD = 11 %) als Kinder mit initialen Leukozytenzahlen unter 10000 (pCCR = 64%; SD = 10%). Die mediane Nachbeobach-tungszeit betr\u00e4gt 4\u00be Jahre (2\u00be-6\u00be Jahre). Bei Kindern mit initialem ZNS-Befall ist die Wahrscheinlichkeit eines ereignisfreien Intervalls von 3 Jahren (pCCR = 24%; SD = 12%) signifikant geringer als bei Kindern ohne ZNS-Befall (pCCR = 50 %; SD = 5%).<\/jats:p>","DOI":"10.1159\/000215968","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T09:41:27Z","timestamp":1240566087000},"page":"78-82","source":"Crossref","is-referenced-by-count":0,"title":["Risikogruppen bei der akuten, nicht-lymphatischen Leuk\u00e4mie im Kindesalter"],"prefix":"10.1159","author":[{"given":"J.","family":"Ritter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Creutzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Schellong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,24]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/215968","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000215968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:59:13Z","timestamp":1777679953000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000215968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,24]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000215968","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,24]]}}}